Guido Reifenberger Selected Research

Alkylating Agents

3/2020	Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma.
12/2019	Longitudinal molecular trajectories of diffuse glioma in adults.
1/2019	A DNA Repair and Cell-Cycle Gene Expression Signature in Primary and Recurrent Glioblastoma: Prognostic Value and Clinical Implications.
1/2018	Transcriptional control of O6 -methylguanine DNA methyltransferase expression and temozolomide resistance in glioblastoma.
3/2016	MicroRNA-138 promotes acquired alkylator resistance in glioblastoma by targeting the Bcl-2-interacting mediator BIM.
7/2014	MGMT testing--the challenges for biomarker-based glioma treatment.
4/2014	Interferon-β induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells.
10/2013	Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
9/2012	Predictive impact of MGMT promoter methylation in glioblastoma of the elderly.
1/2010	MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Guido Reifenberger Research Topics

Disease

131	Neoplasms (Cancer) 06/2022 - 03/2002
98	Glioma (Gliomas) 08/2022 - 07/2002
92	Glioblastoma (Glioblastoma Multiforme) 07/2022 - 10/2002
36	Astrocytoma (Pilocytic Astrocytoma) 05/2022 - 10/2002
15	Brain Neoplasms (Brain Tumor) 06/2022 - 11/2006
12	Medulloblastoma 01/2022 - 10/2003
9	Oligodendroglioma 05/2022 - 02/2003
7	Neoplasm Metastasis (Metastasis) 01/2022 - 08/2002
6	Meningioma (Meningiomas) 12/2021 - 04/2002
6	Carcinogenesis 01/2019 - 03/2004
5	Lymphoma (Lymphomas) 01/2018 - 06/2005
4	Disease Progression 05/2022 - 12/2009
4	Melanoma (Melanoma, Malignant) 01/2020 - 08/2002
4	Residual Neoplasm 01/2018 - 05/2012
4	Intellectual Disability (Idiocy) 01/2017 - 01/2012
3	Ependymoma 08/2021 - 04/2016
3	Thalassemia 01/2017 - 11/2012
3	Primitive Neuroectodermal Tumors (PNET) 02/2016 - 10/2003
3	Neuroepithelial Neoplasms (Gliomatosis Cerebri) 01/2016 - 10/2002
2	Starvation 06/2022 - 02/2014
2	Rhabdoid Tumor (Rhabdoid Tumors) 01/2022 - 01/2018
2	Necrosis 12/2020 - 11/2018
2	Pituitary Neoplasms (Pituitary Adenoma) 03/2018 - 01/2018
2	Neuroblastoma 04/2017 - 05/2004
2	Hypoxia (Hypoxemia) 09/2014 - 04/2010
2	Gliosis 05/2010 - 11/2006

Drug/Important Bio-Agent (IBA)

43	Proteins (Proteins, Gene)FDA Link 07/2022 - 03/2002
36	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 06/2022 - 10/2009
35	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 08/2002
32	Biomarkers (Surrogate Marker)IBA 01/2022 - 08/2005
30	Messenger RNA (mRNA)IBA 02/2022 - 09/2003
26	Temozolomide (Temodar)FDA LinkGeneric 01/2021 - 09/2006
18	Biological ProductsIBA 01/2021 - 07/2002
13	MethyltransferasesIBA 01/2021 - 01/2005
11	Alkylating AgentsIBA 03/2020 - 12/2007
10	ErbB Receptors (EGF Receptor)IBA 01/2021 - 10/2002
9	Histones (Histone)IBA 12/2018 - 07/2008
7	RNA (Ribonucleic Acid)IBA 11/2021 - 08/2006
7	Lomustine (CCNU)FDA Link 10/2021 - 09/2006
7	Tyrosine (L-Tyrosine)FDA Link 01/2020 - 02/2005
7	Codon (Codons)IBA 12/2018 - 04/2004
7	MicroRNAs (MicroRNA)IBA 12/2016 - 05/2010
6	O-(6)-methylguanineIBA 01/2021 - 01/2005
6	Phosphotransferases (Kinase)IBA 11/2019 - 10/2003
6	Amino Acids FDA Link 04/2015 - 11/2006
6	O(6)-Methylguanine-DNA MethyltransferaseIBA 07/2014 - 03/2009
5	ChromatinIBA 02/2022 - 01/2012
5	LigandsIBA 01/2020 - 12/2008
5	epidermal growth factor receptor VIIIIBA 11/2019 - 10/2013
5	Decitabine FDA Link 06/2012 - 03/2004
5	sodium bisulfite FDA Link 05/2010 - 11/2006
4	ProteomeIBA 07/2022 - 03/2010
4	Carrier Proteins (Binding Protein)IBA 02/2022 - 04/2004
4	Long Noncoding RNAIBA 01/2022 - 01/2019
4	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2021 - 01/2016
4	beta CateninIBA 04/2018 - 08/2002
4	Procarbazine (Matulane)FDA Link 09/2012 - 10/2002
4	Complementary DNA (cDNA)IBA 11/2006 - 07/2004
3	Pharmaceutical PreparationsIBA 12/2021 - 12/2008
3	InterferonsIBA 01/2020 - 04/2014
3	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2020 - 10/2003
3	Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA 01/2020 - 10/2003
3	CytokinesIBA 01/2020 - 08/2011
3	AcidsIBA 02/2015 - 04/2011
3	Vincristine (Oncovin)FDA LinkGeneric 09/2012 - 10/2002
3	Small Interfering RNA (siRNA)IBA 08/2011 - 05/2008
3	NestinIBA 03/2011 - 04/2010
3	trichostatin A (A 300)IBA 06/2010 - 03/2004
2	CateninsIBA 06/2022 - 01/2012
2	Immune Checkpoint InhibitorsIBA 05/2022 - 01/2021
2	Transcription Factors (Transcription Factor)IBA 02/2022 - 04/2010
2	Histone Deacetylase InhibitorsIBA 10/2021 - 03/2004
2	alpha-hydroxyglutarateIBA 01/2021 - 11/2018
2	Interferon Type IIBA 01/2020 - 12/2017
2	TOR Serine-Threonine KinasesIBA 01/2020 - 11/2019
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2020 - 02/2016
2	Complement System Proteins (Complement)IBA 11/2018 - 12/2010
2	ParaffinIBA 03/2018 - 05/2015
2	Formaldehyde (Formol)FDA Link 03/2018 - 05/2015
2	NF-kappa B (NF-kB)IBA 01/2018 - 03/2007
2	PeroxiredoxinsIBA 01/2018 - 08/2013
2	SteroidsIBA 01/2018 - 01/2012
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2017 - 07/2002
2	Methionine (L-Methionine)FDA Link 11/2016 - 11/2006
2	LuciferasesIBA 01/2016 - 01/2014
2	DNA Repair EnzymesIBA 07/2014 - 01/2005
2	thiamine triphosphorate (TTP)IBA 12/2013 - 04/2004
2	Mitogen-Activated Protein KinasesIBA 08/2013 - 02/2010
2	EnzymesIBA 07/2013 - 07/2012
2	Tretinoin (Retinoic Acid)FDA LinkGeneric 05/2011 - 04/2011
2	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 04/2011 - 04/2010
2	Glial Fibrillary Acidic ProteinIBA 05/2010 - 07/2009
2	Tumor Suppressor Protein p14ARF (p14ARF)IBA 07/2009 - 11/2004

Therapy/Procedure

43	Therapeutics 05/2022 - 02/2003
37	Drug Therapy (Chemotherapy) 08/2022 - 10/2002
19	Radiotherapy 08/2022 - 10/2002
11	Chemoradiotherapy 06/2022 - 10/2008
4	Immunotherapy 05/2022 - 01/2015
2	Molecular Targeted Therapy 11/2019 - 07/2002
2	Precision Medicine 07/2017 - 01/2010